D. R. Cody

Tyrosine Kinase Inhibitors. Part 5. Synthesis and Structure‐Activity Relationships for 4‐((Phenylmethyl)amino)‐ and 4‐(Phenylamino) quinazolines as Potent Adenosine 5′‐Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor.

W. Denny, G. Rewcastle, A. Bridges, 1995 .

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Tyrosine Kinase Inhibitors. Part 10. Isomeric 4‐((3‐Bromophenyl)amino) pyrido(d)pyrimidines are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor (EGFR) .

W. Denny, G. Rewcastle, A. Bridges, 1996 .

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1995, Journal of medicinal chemistry.

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.

W. Denny, G. Rewcastle, A. Bridges, 1996, Journal of medicinal chemistry.

Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinase by 4-(alpha-phenethylamino)quinazolines.

A. Bridges, D. W. Fry, H. Zhou, 1995, Bioorganic & medicinal chemistry.